Cochrane Review Group

Infectious Diseases

135 systematic reviews in Infectious Diseases ask 1,518 questions. 8.9% have no studies to answer them, 23.1% rest on very low certainty evidence and 30.5% reach moderate or high certainty.

Reviews

135

Questions

1,518

current versions

No studies

8.9%

Moderate or high

30.5%

No studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Infectious Diseases

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment All‐cause mortality – at 28 to 30 days, or in‐hospital · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	RR 0.84 [0.49, 1.46]	11 studies · 3459 participants	Very low
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Progression to invasive mechanical ventilation · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	RR 0.86 [0.68, 1.09]	8 studies · 1383 participants	Very low
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Time to clinical improvement (defined as time to a 2‐point reduction in patients’ admission status on WHO’s ordinal scale) · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	HR 1.13 [0.69, 1.83]	4 studies · 721 participants	Very low
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Virologically confirmed dengue case incidence (any severity, any phenotype) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of dengue RNA in the mosquito population · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Mosquito density (for population suppression strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of Wolbachia‐carrying mosquitoes (for population replacement strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Adverse events potentially related to Wolbachia‐carrying Aedes deployments · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR NRCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies

Reviews 135

Vector and reservoir control for preventing leishmaniasis

González, U, Pinart, M, et al. · Cochrane Database of Systematic Reviews · 2015

Infectious Diseases

Thinnest evidence

Reviews 135

Vector and reservoir control for preventing leishmaniasis

Intermittent preventive antimalarial treatment for children with anaemia

Artemisinin‐naphthoquine for treating uncomplicated Plasmodium falciparum malaria

Drugs for treating urinary schistosomiasis

Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment

Corticosteroids for dengue infection

Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment

Intermittent versus daily therapy for treating tuberculosis in children

Antimicrobial drugs for treating cholera

Rapid diagnostic tests versus clinical diagnosis for managing people with fever in malaria endemic settings

Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease

Pre‐referral rectal artesunate for severe malaria

Dihydroartemisinin‐piperaquine for treating uncomplicated Plasmodium falciparum malaria

Adjunctive steroid therapy for managing pulmonary tuberculosis

Drugs for treating Schistosoma mansoni infection

Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine

Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive)

Lactose avoidance for young children with acute diarrhoea

Probiotics for treating persistent diarrhoea in children

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV‐negative people at risk of active TB

Treating BCG‐induced disease in children

Artemisinin‐based combination therapy for treating uncomplicated Plasmodium vivax malaria

Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea

Antimicrobials for treating symptomatic non‐typhoidal Salmonella infection

Antipyretic measures for treating fever in malaria